Cipla’s Milestone Moment: USFDA Greenlights Protein-Bound Paclitaxel Launch

Unknown Apr 02, 2026 850 Views

Cipla Limited has reached a major milestone with the approval of its protein-bound paclitaxel formulation by the United States Food and Drug Administration (USFDA). This novel drug is indicated for the treatment of metastatic triple-negative breast cancer (TNBC), a difficult-to-treat condition wi...